Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. (Q39705167)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

0 references

multicenter clinical trial

0 references

rheumatoid arthritis

0 references

mesenchymal stem cell

1 reference

based on heuristic

inferred from title

Federico Díaz-González

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Jose M Álvaro-Gracia

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Juan A Jover

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Rosario García-Vicuña

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Luis Carreño

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Alberto Alonso

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Sara Marsal

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Francisco Blanco

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Victor M Martínez-Taboada

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Peter Taylor

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Cristina Martín-Martín

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Olga DelaRosa

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Ignacio Tagarro

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

0 references

publication date

7 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

76

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

196-202

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Human adipose tissue is a source of multipotent stem cells

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Human placenta-derived cells have mesenchymal stem/progenitor cell potential.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Immunomodulatory properties and therapeutic application of mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Interactions between human mesenchymal stem cells and natural killer cells

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Multilineage potential of adult human mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Mesenchymal stem cells: biology and potential clinical uses

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

The allogeneic umbilical cord mesenchymal stem cells regulate the function of T helper 17 cells from patients with rheumatoid arthritis in an in vitro co-culture system

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Defining the risks of mesenchymal stromal cell therapy

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Immunological aspects of allogeneic mesenchymal stem cell therapies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Adipose-derived stem cells for regenerative medicine

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Assessing the safety of biologic agents in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Washing red cells after leucodepletion does not decrease human leukocyte antigen sensitization risk in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Mesenchymal stromal cells for treatment of arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208918

21 January 2018

Spontaneous human adult stem cell transformation.

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1158/0008-5472.CAN-04-4194

Identifiers

10.1136/ANNRHEUMDIS-2015-208918

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27269294%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39705167&oldid=2089040655"